0 44

Cited 0 times in

Real-world efficacy and safety of nebivolol in Korean patients with hypertension from the BENEFIT KOREA study

Authors
 Jinho Shin  ;  Yu Jeong Choi  ;  Geu-Ru Hong  ;  Dong Woon Jeon  ;  Dae-Hyeok Kim  ;  Young Youp Koh  ;  Giuseppe Mancia  ;  Athanasios J Manolis  ;  Hyuck-Jun Yoon  ;  Sang Won Park 
Citation
 JOURNAL OF HYPERTENSION, Vol.38(3) : 527-535, 2020-03 
Journal Title
JOURNAL OF HYPERTENSION
ISSN
 0263-6352 
Issue Date
2020-03
MeSH
Antihypertensive Agents / therapeutic use* ; Humans ; Hypertension / drug therapy* ; Nebivolol / therapeutic use* ; Prospective Studies ; Republic of Korea
Keywords
add-on therapy ; Asian ; combination therapy ; essential hypertension ; monotherapy ; nebivolol
Abstract
Objective: The efficacy and safety of nebivolol in patients with hypertension is well established, but its effect in Asian patients with essential hypertension in the real world has not been studied. Methods: Adult South Korean patients with essential hypertension, with or without comorbidities, were enrolled to participate in this prospective, single-arm, open, observational study; 3011 patients received nebivolol either as monotherapy or add-on therapy. Changes in SBP, DBP and heart rate (HR) at 12 and 24 weeks were evaluated. Subgroup analysis for BP changes in newly diagnosed (de novo) patients and those receiving other antihypertensives at study entry were also conducted. Results: Nebivolol significantly decreased mean SBP and DBP at 12 and 24 weeks compared with baseline (P < 0.0001). A significant reduction in HR was also observed at 12 and 24 weeks (P < 0.0001). The reductions of SBP and DBP were notably greater when nebivolol was used as monotherapy in de novo patients (P < 0.0001) and as add-on therapy to existing antihypertensives (angiotensin II receptor blockers, angiotensin-converting enzyme inhibitors and calcium channel blockers; P < 0.0001). Majority of the reported adverse events were mild; the most common adverse events were dizziness (1.3%), headache (1.0%) and dyspnea (0.9%). Conclusion: Despite the limitations associated with observational studies, this real-world study in Asian patients with essential hypertension with and without comorbidities, demonstrated the efficacy and safety of once daily nebivolol, either as monotherapy or add-on therapy.
Full Text
https://journals.lww.com/jhypertension/Fulltext/2020/03000/Real_world_efficacy_and_safety_of_nebivolol_in.23.aspx
DOI
10.1097/HJH.0000000000002296
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Hong, Geu Ru(홍그루) ORCID logo https://orcid.org/0000-0003-4981-3304
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/190207
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links